Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Safety: early-phase trial registry

3 of 11 indexed Safety trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,577 of 28,707 conditions by registered trial count.

11 US clinical trials · 3 currently recruiting · #1,577 of 28,707 conditions by registered trial count

Safety: 11 US clinical trials tracked, 3 recruiting.

Safety is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Altasciences Company, running 1 of these trials.

Enrollment posture brief

Registry condition safety

OPEN 3 | RECR 27% | LATE 2 | EARLY 6 | RANK #1577 | SPON 1

Nearest open-share peer: Atherosclerotic Cardiovascular Disease (27% recruiting · 22 trials)

Acute Pancreatitis81.8%Acute Stroke45.5%Acquired Brain Injury36.4%Safety (this)27%Acute Lung Injury9.1%
Open-enrollment share among volume-matched conditions near Safety

Safety lists 3 open slots (27% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Safety on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Safety is recruiting below its size-band peers.

    3 of 11 indexed trials (27.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Safety trials is spread across many organizations.

    Altasciences Company accounts for 1 of 11 trials (9.1%). 11 distinct sponsors appear on at least one study for this condition label.

  3. Most Safety trials plan to enrol fewer than 100 people.

    Median target enrolment is 60 among the 11 trials that report a genuine target (sentinel values excluded). 7 of those (63.6%) plan for fewer than 100 participants.

  4. Safety research is mostly interventional.

    10 interventional and 1 observational studies make up this index (90.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 16Phase 31Phase 41

Open and recent trials

11 total, page 1 of 1

RECRUITING Phase 1 60 participants

Curcumin and Retinal Study

Texas Tech University Health Sciences Center

NCT05774704

RECRUITING Phase 1 46 participants

Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination

Basilea Pharmaceutica

NCT06733675

RECRUITING Phase 3 40 participants

PyloPlus Urea Breath Test System Pediatric Safety and Efficacy Study

ARJ Medical

NCT05276557

ACTIVE NOT RECRUITING 250 participants

Prospective G7 Dual Mobility Total Hip PMCF

Zimmer Biomet

NCT03308929

COMPLETED NA 400 participants

Developing a Dyadic Shared Decision Making Tool About Firearm Storage

Seattle Children's Hospital

NCT05451355

COMPLETED Phase 1 159 participants

Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects

Actelion

NCT02206204

COMPLETED Phase 1 120 participants

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Novartis Pharmaceuticals

NCT01576666

COMPLETED Phase 4 98 participants

Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy Study

Duke University

NCT06503900

COMPLETED Phase 1 40 participants

Single Ascending Doses of Kratom in Healthy Nondependent Adults With Opioid Experience

Altasciences Company

NCT06072170

COMPLETED NA 40 participants

Safety and Tolerability of a Novel Amino-acid Based Hydration Drink in Healthy Volunteers

University of Memphis

NCT05592951

COMPLETED Phase 1 32 participants

Study to Assess the Safety and the Phosphate Binding Capacity of Renazorb

Spectrum Pharmaceuticals

NCT01560884

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 3 1
Phase 4 1

Named interventions

Most-linked intervention names on Safety records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

moxifloxacin-matching placebo Drug
1 trials
placebo for selexipag Drug
1 trials
selexipag Drug
1 trials
Renazorb 6000 mg/day Drug
1 trials
Renazorb 4500 mg/day Drug
1 trials
Renazorb 3000 mg/day Drug
1 trials
Renazorb 1500 mg/day Drug
1 trials
Liquid IV with amino acids (three servings) Dietary supplement
1 trials

US sites by state

Facility locations filed on Safety trials. A trial with sites in several states counts in each.

Texas 3 trials
North Carolina 3 trials
Oregon 2 trials
Massachusetts 2 trials
Kansas 2 trials
Florida 2 trials
Washington 1 trials
Virginia 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Safety page

11 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Safety condition card totals 11 registered trials; most-linked intervention moxifloxacin-matching placebo; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.